

## **The board of directors' of Medicover AB (publ) statement under Chapter 19 Section 22 of the Companies Act**

The board of directors of Medicover AB (publ) has proposed that the annual general meeting to be held on 26 April 2018 resolves to authorise the board of directors to acquire own class C shares of Medicover AB (publ). The board of directors considers, in view of what is stated below, that the proposed authorisation for the board of directors to acquire own shares is justifiable with respect to the requirements that the business' nature, scale and risk place on the amount of equity, and the need for Medicover to strengthen the balance sheet, liquidity and position in other aspects.

### **Equity**

The board of directors considers that the equity of Medicover will be of sufficient amount after the proposed acquisitions, taking into account the business' nature, scale and the risks that the business is associated with and the current economic situation, historical development and forecasts for Medicover as well as for the market.

### **Need of strengthening the balance sheet, liquidity and position in other aspects**

The board of directors has made a comprehensive assessment of Medicover's financial position and its ability to, in the long term, fulfill its undertakings. As stated in Medicover's annual report for the 2017 financial year, the non-restricted equity of Medicover as per 31 December 2017 was EUR 403,828,139.

The proposed acquisitions does not affect Medicover's ability to in due time fulfill its present and anticipated financial obligations or Medicover's ability to implement planned investments.

The board of directors has also considered other known matters that may affect Medicover's financial position and that have not been considered within the scope of the above mentioned. No other matter that would make the proposed acquisitions unjustifiable has been identified during such analysis.

---

Stockholm in March 2018  
Medicover AB (publ)  
The nomination committee